Novato, CA, United States of America

Scott C Baraban

USPTO Granted Patents = 14 

 

 

Average Co-Inventor Count = 1.5

ph-index = 2

Forward Citations = 19(Granted Patents)


Company Filing History:


Years Active: 2015-2025

Loading Chart...
Loading Chart...
Loading Chart...
14 patents (USPTO):Explore Patents

Title: Scott C Baraban: Innovator in Epilepsy Treatment

Introduction

Scott C Baraban is a prominent inventor based in Novato, CA (US), known for his significant contributions to the field of epilepsy treatment. With a total of 14 patents to his name, Baraban has made remarkable strides in developing innovative methods and compounds aimed at addressing epilepsy disorders.

Latest Patents

Among his latest patents, Baraban has focused on 5HT agonists for treating disorders. His work includes methods for treating epilepsy using a 5HT receptor agonist or a pharmaceutically acceptable salt thereof. Additionally, he has developed compounds and methods for treating an epileptic disorder, which involve the use of clemizole, a clemizole analog, or pharmaceutical salts thereof.

Career Highlights

Baraban's career is marked by his association with the University of California, where he has been able to leverage his expertise in neuroscience and pharmacology. His research has not only advanced scientific understanding but has also paved the way for potential therapeutic applications in treating epilepsy.

Collaborations

Throughout his career, Baraban has collaborated with notable colleagues, including Arturo Alvarez-Buylla and Arnold Kriegstein. These partnerships have enriched his research and contributed to the development of innovative solutions in the field.

Conclusion

Scott C Baraban stands out as a key figure in the innovation of epilepsy treatments, with a strong portfolio of patents and collaborations that highlight his dedication to advancing medical science. His work continues to inspire future research and development in the field of neurology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…